 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Black Diamond Therapeutics (NASDAQ:BDTX  Get Free Report)s stock had its buy rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Wednesday...

Black Diamond Therapeutics (NASDAQ:BDTX) Stock Rating Reaffirmed by HC Wainwright

CAMBRIDGE, Mass. and NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target...

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023...

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX  Get Free Report) was the recipient of a significant growth in short interest in October. As of October 15th, there was short interest totalling...

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Growth in Short Interest

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX  Get Free Report) major shareholder Growth N. V. Biotech purchased 400,000 shares of the stock in a transaction on Tuesday, October 17th. The...

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Major Shareholder Growth N. V. Biotech Buys 400,000 Shares of Stock

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Black Diamond Therapeutics presents data from Phase 1 trial of BDTX-1535

Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes No new safety or tolerability signal reported across all three...

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target...

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX  Get Free Report) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totalling...

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Significant Increase in Short Interest

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX  Get Free Report) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totalling...

Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Watchers	2,020
52-Wk Low	$1.22
52-Wk High	$6.85

Market Cap	$116.7M
Volume (M)	148,105.00
52-Wk High	$6.85
52-Wk Low	$1.22

BDTX Black Diamond Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals